XTLB (XTL Biopharmaceuticals Ltd.) Enterprise Value-to-Revenue Coefficient

Public company logo of xtlbio.com (XTLB)

XTL Biopharmaceuticals focuses on proprietary molecules to combat autoimmune pathologies, where success depends on testing. The company's environmental strategy is based on "green chemistry" for wastewater treatment. A stable R&D core ensures the preservation of key competencies. This EV/Sales valuation chart on GURU.Markets reflects the price-to-sales dynamics, with the 0.00 metric serving as the target level.

XTL Bio (XTLB) - Company Value to Revenue from 11/23/2025 to 11/20/2026

XTL Bio - analytical breakdowns and key metrics (XTLB)

- share price and consensus valuation forecast:
- business market valuation indicators:
Initial company analysis:XTLB, xtlbio.com
Flagship merchandise of XTL Biopharmaceuticals, Ltd.

This indicator measures the aggregate value of assets and liabilities relative to annual turnover, allowing investors to filter out market noise and assess the real value of the business without the influence of debt load. Analyzing the enterprise value-to-revenue ratio helps determine the extent to which the market currently prices in the success of the XTL Biopharmaceuticals (XTLB) strategy of acquiring late-stage developments to mitigate biotech risks.

Competitor analysis

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Dianthus Therapeutics Inc|Pharvaris NV (PHVS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple ABCL|Tourmaline Corp - Company Value to Revenue Ratio|EV/Sales Multiple PGEN (precigen.com)|Enterprise Value-to-Sales Ratio pharming.com|NKTR - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Upstream Bio Corp|ZBIO: EV/Sales Multiple|Company Value to Revenue Immunome, Inc.|Company Value to Revenue GOSS|KALV: Business Value to Revenue|EV/Sales Multiple SEPN|Company Value to Revenue Pieris Pharmaceuticals, Inc. PVLA|EV/Sales Multiple SVRA (Savara Inc)|EV/Sales Multiple Rigel Pharmaceuticals RIGL|AnaptysBio Inc. - EV/Sales Multiple|Astria Therapeutics - Enterprise Value-to-Revenue Coefficient|ENGN: EV/Sales Multiple|RAPT - Total Company Value-to-Revenue Ratio|Company Value to Revenue JBIO|Aclaris (ACRS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple KYTX|Company Value to Revenue Tiziana Life Sciences TLSA|EV/Sales Multiple CABA (cabalettabio.com)|Enterprise Value-to-Revenue Coefficient VTYX (Ventyx Bio)|Theratechnologies, Inc - EV/Sales Multiple|AVTX (Avalo Therapeutics Inc.) - Company Value to Revenue Ratio|eledon.com (ELDN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio AGEN|CLYM (climbbio.com) - EV/Sales Multiple|EV/Sales Multiple zurabio.com|Enterprise Value-to-Revenue Ratio aTyr (ATYR)|ADAG - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio ImageneBio Inc IMA|EV/Sales Multiple Shattuck Labs, Inc. STTK|EQ - Enterprise Value-to-Revenue Ratio|connectbiopharm.com (CNTB) - Company Value to Revenue|IMUX (Immunic) - Company Value to Revenue|Atara Biotherapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio InflaRx|Company Value to Revenue x4pharma.com (XFOR)|EV/Sales Multiple ACET|Company Value to Revenue Celularity Corp CELU|INmune Bio Inc - Company Value to Revenue|BRNS (Barinthus Bio) - Enterprise Value to Sales Volume|KZR - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio sabbiotherapeutics.com SABS|Akari Therapeutics PLC (AKTX) - Enterprise Value-to-Revenue Ratio|ENLV - Total Company Value-to-Revenue Ratio|QTTB (Q32 Bio) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple GeoVax Labs Inc GOVX|Enterprise Value-to-Revenue Ratio Edesa Biotech (EDSA)|Company Value to Revenue iBio IBIO|Carisma Therapeutics Inc - Company Value to Revenue|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD